title: Clinical experience of integrative cancer immunotherapy with GcMAF.
abstract: BACKGROUND
  Immunotherapy has become an attractive new strategy in the treatment of cancer. The laboratory and clinical study of cancer immunotherapy is rapidly advancing. However, in the clinical setting, the results of cancer immunotherapy are mixed. We therefore contend that cancer immunotherapy should be customized to each patient individually based on their immune status and propose an integrative immunotherapy approach with second-generation group-specific component macrophage activating factor (GcMAF)-containing human serum.
  
  
  METHODS
  The standard protocol of our integrative cancer immunotherapy is as follows: i) 0.5 ml GcMAF-containing human serum is administered intramuscularly or subcutaneously once or twice per week for the duration of cancer therapy until all cancer cells are eradicated; ii) hyper T/natural killer (NK) cell therapy is given once per week for six weeks; iii) high-dose vitamin C is administered intravenously twice per week; iv) alpha lipoic acid (600 mg) is administered orally daily; v) vitamin D3 (5,000-10,000 IU) is administered orally daily.
  
  
  RESULTS
  By March 2013, Saisei Mirai have treated over 345 patients with GcMAF. Among them we here present the cases of three patients for whom our integrative immunotherapy was remarkably effective.
  
  
  CONCLUSIONS
  The results of our integrative immunotherapy seem hopeful. We also plan to conduct a comparative clinical study.>
authors.affiliation: Department of Life System, Institute of Technology and Science, Graduate School, University of Tokushima, Tokushima, Japan.
authors.forename: Toshio
authors.initials: T
authors.lastname: Inui
authors.forename: Daisuke
authors.initials: D
authors.lastname: Kuchiike
authors.forename: Kentaro
authors.initials: K
authors.lastname: Kubo
authors.forename: Martin
authors.initials: M
authors.lastname: Mette
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Uto
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Hori
authors.forename: Norihiro
authors.initials: N
authors.lastname: Sakamoto
mesh_terms: D000368:Aged; D001205:Ascorbic Acid / Q000008:administration & dosage; D001859:Bone Neoplasms / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D064987:Cell- and Tissue-Based Therapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007167:Immunotherapy; D007273:Injections, Intramuscular; D007279:Injections, Subcutaneous; D008113:Liver Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008175:Lung Neoplasms / Q000276:immunology / Q000556:secondary / Q000628:therapy*; D016215:Macrophage-Activating Factors / Q000008:administration & dosage*; D008297:Male; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D008063:Thioctic Acid / Q000008:administration & dosage; D013953:Thymus Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D014809:Vitamin D-Binding Protein / Q000008:administration & dosage*
chemical_list: D016215:Macrophage-Activating Factors; D014809:Vitamin D-Binding Protein; C101908:vitamin D-binding protein-macrophage activating factor; D008063:Thioctic Acid; D001205:Ascorbic Acid
keywords: GcMAF; Immunotherapy; alpha lipoic acid; high-dose vitamin C; hyper T/NK cells